More than chemotaxis: A new anti-tumor DC vaccine modified by rAAV2-SLC

Molecular Immunology

Volumn 44, Issue 15, 2007, Pages 3797-3804

  Liang, Chun min ^a,b   Ye, Sheng long ^b   Zhong, Cui ping ^a   Zheng, Ning ^b   Bian, Wei ^c   Sun, Rui xia ^b   Chen, Jun ^b   Li, Ri lun ^a   Zhou, Shuang ^a   Liu, Yin kun ^b  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

Author keywords

BMDC; PTX; rAAV2; SLC

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; DENDRITIC CELL VACCINE; PARVOVIRUS VECTOR; PERTUSSIS TOXIN; RECOMBINANT ADENOASSOCIATED VIRUS 2 VECTOR; SECONDARY LYMPHOID TISSUE CHEMOKINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CANCER IMMUNIZATION; CANCER MODEL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHEMOTAXIS; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; EVALUATION; FEMALE; FOOT PAD; FOOT PAD DRUG ADMINISTRATION; GENETIC TRANSFECTION; LIVER CELL CARCINOMA; LYMPHOID ORGAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; CANCER VACCINES; CHEMOKINES, CC; CHEMOTAXIS; DENDRITIC CELLS; DEPENDOVIRUS; FEMALE; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; PERTUSSIS TOXIN; TRANSDUCTION, GENETIC; TRANSFECTION;

EID: 34249341379     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2007.03.026     Document Type: Article

References (32)

1. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 (1998) 245-252
2. Bartlett J.S., Wilcher R., and Samulski R.J. Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors. J. Virol. 74 (2000) 2777-2785
3. Bjorklund A., Kirik D., Rosenblad C., Georgievska B., Lundberg C., and Mandel R.J. Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Res. 886 (2000) 82-98
4. Cao X., Zhang W., He L., Xie Z., Ma S., Tao Q., Yu Y., Hamada H., and Wang J. Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity. J. Immunol. 161 (1998) 6238-6244
5. Crittenden M., Gough M., Harrington K., Olivier K., Thompson J., and Vile R.G. Expression of inflammatory chemokines combined with local tumor destruction enhances tumor regression and long-term immunity. Cancer Res. 63 (2003) 5505-5512
6. During M.J., Samulski R.J., Elsworth J.D., Kaplitt M.G., Leone P., Xiao X., Li J., Freese A., Taylor J.R., Roth R.H., Sladek, O'Malley K.L., and Redmond Jr. D.E. In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector. Gene Ther. 5 (1998) 820-827
7. Furumoto K., Soares L., Engleman E.G., and Merad M. Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. J. Clin. Invest. 113 (2004) 774-783
8. Gunn M.D., Tangemann K., Tam C., Cyster J.G., Rosen S.D., and Williams L.T. A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naive T lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 258-263
9. Guo J., Wang B., Zhang M., Chen T., Yu Y., Regulier E., Homann H.E., Qin Z., Ju D.W., and Cao X. Macrophage-derived chemokine gene transfer results in tumor regression in murine lung carcinoma model through efficient induction of antitumor immunity. Gene Ther. 9 (2002) 793-803
10. Hou W.Q., Wu Y., Sun S., Shi M., Sun Y., Yang C., Pei G., Gu Y., Zhong C., and Sun B. Pertussis toxin enhances Th1 responses by stimulation of dendritic cells. J. Immunol. 170 (2003) 1728-1736
11. Hromas R., Kim C.H., Klemsz M., Krathwohl M., Fife K., Cooper S., Schnizlein-Bick C., and Broxmeyer H.E. Isolation and characterization of Exodus-2, a novel C-C chemokine with a unique 37-amino acid carboxyl-terminal extension. J. Immunol. 159 (1997) 2554-2558
12. Huang A.Y., Golumbek P., Ahmadzadeh M., Jaffee E., Pardoll D., and Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264 (1994) 961-965
13. Jooss K., Yang Y., Fisher J.K., and Wilson J.M. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J. Virol. 72 (1998) 4212-4223
14. Kessler P.D., Podsakoff G.M., Chen X., McQuiston S.A., Colosi P.C., Matelis L.A., Kurtzman G.J., and Byrne B.J. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 14082-14087
15. Kirk C.J., Hartigan-O'Connor D., Nickoloff B.J., Chamberlain J.S., Giedlin M., Aukerman L., and Mule J.J. T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy. Cancer Res. 61 (2001) 2062-2070
16. Miyata T., Yamamoto S., Sakamoto K., Morishita R., and Kaneda Y. Novel immuno-therapy for peritoneal dissemination of murine colon cancer with macrophage inflammatory protein-1beta mediated by a tumor-specific vector, HVJ cationic liposomes. Cancer Gene Ther. 8 (2001) 852-860
17. Nagira M., Imai T., Yoshida R., Takagi S., Iwasaki M., Baba M., Tabira Y., Akagi J., Nomiyama H., and Yoshie O. A lymphocyte-specific CC chemokine, secondary lymphoid tissue chemokine (SLC), is a highly efficient chemoattractant for B cells and activated T cells. Eur. J. Immunol. 28 (1998) 1516-1523
18. Nakai H., Montini E., Fuess S., Storm T.A., Grompe M., and Kay M.A. AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat. Genet. 34 (2003) 297-302
19. Ponnazhagan S., Curiel D.T., Shaw D.R., Alvarez R.D., and Siegal G.P. Adeno-associated virus for cancer gene therapy. Cancer Res. 61 (2001) 6313-6321
20. Reif K., Ekland E.H., Ohl L., Nakano H., Lipp M., Forster R., and Cyster J.G. Balanced responsiveness to chemoattractants from adjacent zones determines B-cell position. Nature 416 (2002) 94-99
21. Robertson M.J., Williams B.T., Christopherson II K., Brahmi Z., and Hromas R. Regulation of human natural killer cell migration and proliferation by the exodus subfamily of CC chemokines. Cell Immunol. 199 (2000) 8-14
22. Sanlioglu S., Benson P., and Engelhardt J.F. Loss of ATM function enhances recombinant adeno-associated virus transduction and integration through pathways similar to UV irradiation. Virology 268 (2000) 68-78
23. Satoh W., Satoh W., Hirai Y., Tamayose K., and Shimada T. Site-specific integration of an adeno-associated virus vector plasmid mediated by regulated expression of rep based on Cre-loxP recombination. J. Virol. 74 (2000) 10631-10638
24. Sharm S., Stolina M., Luo J., Strieter R.M., Burdick M., Zhu L.X., Batra R.K., and Dubinett S.M. Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J. Immunol. 164 (2000) 4558-4563
25. Sharma S., Yang S.C., Hillinger S., Zhu L.X., Huang M., Batra R.K., Lin J.F., Burdick M.D., Strieter R.M., and Dubinett S.M. SLC/CCL21-mediated anti-tumor responses require IFNgamma, MIG/CXCL9 and IP-10/CXCL10. Mol. Cancer 2 (2003) 22
26. Soto H., Wang W., Strieter R.M., Copeland N.G., Gilbert D.J., Jenkins N.A., Hedrick J., and Zlotnik A. The CC chemokine 6Ckine binds the CXC chemokine receptor CXCR3. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 8205-8210
27. Stein J.V., Rot A., Luo Y., Narasimhaswamy M., Nakano H., Gunn M.D., Matsuzawa A., Quackenbush E.J., Dorf M.E., and vonAndrian U.H. The CC chemokine thymus-derived chemotactic agent 4 (TCA-4, secondary lymphoid tissue chemokine, 6Ckine, exodus-2) triggers lymphocyte function-associated antigen 1-mediated arrest of rolling T lymphocytes in peripheral lymph node high endothelial venules. J. Exp. Med. 191 (2000) 61-76
28. Tolba K.A., Bowers W.J., Muller J., Housekneckt V., Giuliano R.E., Federoff H.J., and Rosenblatt J.D. Herpes simplex virus (HSV) amplicon-mediated codelivery of secondary lymphoid tissue chemokine and CD40L results in augmented antitumor activity. Cancer Res. 62 (2002) 6545-6551
29. Vicari A.P., Ait-Yahia S., Chemin K., Mueller A., Zlotnik A., and Caux C. Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms. J. Immunol. 165 (2000) 1992-2000
30. Warren P., Song W., Holle E., Holmes L., Wei Y., Li J., Wagner T., and Yu X. Combined HSV-TK/GCV and secondary lymphoid tissue chemokine gene therapy inhibits tumor growth and elicits potent antitumor CTL response in tumor-bearing mice. Anticancer Res. 22 (2002) 599-604
31. Xu R., Sun X., Tse L.Y., Li H., Chan P.C., Xu S., Xiao W., Kung H.F., Krissansen G.W., and Fan S.T. Long-term expression of angiostatin suppresses metastatic liver cancer in mice. Hepatology 37 (2003) 1451-1460
32. Yang S.C., Hillinger S., Riedl K., Zhang L., Zhu L., Huang M., Atianzar K., Kuo B.Y., Gardner B., Batra R.K., Strieter R.M., Dubinett S.M., and Sharma S. Introtumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity. Clin. Cancer Res. 10 (2004) 2891-2901